ADI Capital — Abu Dhabi Islamic Bank Egypt’s (ADIB Egypt) investment banking arm — announced on Monday that it has acted as the exclusive sell-side adviser to the shareholders of Nerhadou International for Pharmaceuticals and Nutraceuticals (Nerhadou) for a significant minority stake investment to Affirma Capital and StonePine ACE Partners Limited (StonePine).
Nerhadou is one of the largest and fastest-growing nutraceutical and pharmaceutical players and a pioneer oral dispersible film (ODF) manufacturer in Egypt. This transaction acts as the foundation to solidify Nerhadou’s plans to penetrate export markets.
“This is an exciting milestone in terms of new territory for ADI Capital. It marks our first M&A transaction since the incorporation of this business line back in 2020. We are honoured to have introduced a new top-tier private equity firm to the Egyptian market, which reflects the attractiveness of the Egyptian economy to international investors,” CEO of ADI Capital Hatem Al-Demerdash commented.
“We are delighted to have worked closely with the founders of Nerhadou to help them achieve their strategic objectives through the execution of this transaction,” said Ahmed Al-Zahhar, the Director of M&A at ADI Capital.
ADI Capital and Al-Tamimi & Co. acted as the exclusive sell-side adviser and legal advisers, respectively, to the shareholders on this transaction.
Meanwhile, Renaissance Capital and White & Case acted as the exclusive buy-side adviser and legal advisers, respectively, to Affirma Capital and StonePine.
Final transaction closing is subject to customary closing conditions and regulatory approvals.